ArticleInternational journal of proteomics2013
Serum biomarkers identification by mass spectrometry in high-mortality tumors.
Article in International journal of proteomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 44 citations in OpenAlex.
- A Sensitive Multichannel Fluorescent Polymer Sensor Array for the Detection of Protein Fluctuations in Serum.Sensors (Basel, Switzerland) · 2026Article
- Investigating the Secreted Proteome of Primary and Metastatic Human Brain Tumour Explants Maintained on a Miniaturised Perfusion Device.Current oncology (Toronto, Ont.) · 2026Article
- In Search of Ideal Solutions for Cancer Diagnosis: From Conventional Methods to Protein Biomarkers in Liquid Biopsy.Proteomes · 2025Review
- Advances in Intraoperative Glioma Tissue Sampling and Infiltration Assessment.Brain sciences · 2023Review
- Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer.Genes & diseases · 2023Review
- Nipple fluid for breast cancer diagnosis using the nanopore of Phi29 DNA-packaging motor.Nanomedicine : nanotechnology, biology, and medicine · 2023Article
- Challenges in Metabolomics-Based Tests, Biomarkers Revealed by Metabolomic Analysis, and the Promise of the Application of Metabolomics in Precision Medicine.International journal of molecular sciences · 2022Review
- Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers.Proteomes · 2021Review
- Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study.Diagnostics (Basel, Switzerland) · 2020Article
- Construction of a CXC Chemokine-Based Prediction Model for the Prognosis of Colon Cancer.BioMed research international · 2020Article
- P-MAPA and IL-12 Differentially Regulate Proteins Associated with Ovarian Cancer Progression: A Proteomic Study.ACS omega · 2019Article
- Liquid chromatography-mass spectrometry identification of serum biomarkers for nocturia in aged men.World journal of urology · 2019Article
- The Relevance of Mass Spectrometry Analysis for Personalized Medicine through Its Successful Application in Cancer "Omics".International journal of molecular sciences · 2019Review
- Review
- Review
- Single Domain Antibodies as New Biomarker Detectors.Diagnostics (Basel, Switzerland) · 2017Review
- Application Value of Mass Spectrometry in the Differentiation of Benign and Malignant Liver Tumors.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.Scientific reports · 2017Article
- Metabolomics for the masses: The future of metabolomics in a personalized world.New horizons in translational medicine · 2017Review
- Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.The Eurasian journal of medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer affects millions of people worldwide. Tumor mortality is substantially due to diagnosis at stages that are too late for therapies to be effective. Advances in screening methods have improved the early diagnosis, prognosis, and survival for some cancers. Several validated biomarkers are currently used to diagnose and monitor the progression of cancer, but none of them shows adequate specificity, sensitivity, and predictive value for population screening. So, there is an urgent need to isolate novel sensitive, specific biomarkers to detect the disease early and improve prognosis, especially in high-mortality tumors. Proteomic techniques are powerful tools to help in diagnosis and monitoring of treatment and progression of the disease. During the last decade, mass spectrometry has assumed a key role in most of the proteomic analyses that are focused on identifying cancer biomarkers in human serum, making it possible to identify and characterize at the molecular level many proteins or peptides differentially expressed. In this paper we summarize the results of mass spectrometry serum profiling and biomarker identification in high mortality tumors, such as ovarian, liver, lung, and pancreatic cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.